Exagen Inc. Showcases Autoimmune Diagnostic Leadership at Q4 2025 Conferences
Dateline — CARLSBAD, Calif., November 11, 2025:Exagen Inc. (Nasdaq: XGN), a leader in autoimmune diagnostics, has announced its participation...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Dateline — CARLSBAD, Calif., November 11, 2025:Exagen Inc. (Nasdaq: XGN), a leader in autoimmune diagnostics, has announced its participation...
